News | Left Atrial Appendage (LAA) Occluders | August 21, 2020

COVID-19 Boosts Demand for Left Atrial Appendage Closure Devices Market

COVID-19 worldwide increased demand for LAA occluder devices to reduce clinic visits and hospitalizations in high risk bleeding patients

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from atrial fibrillation (AF) and the growing geriatric population are the major factors expected to propel the growth of the global left atrial appendage closure devices market. In addition, the rising cases of COVID-19 is resulting in increasing demand for left atrial appendage (LAA) closure devices to ween patients off of anticoagulation and eliminate the need for regular Coumadin clinic visits for INR testing used to maintain the drug at therapeutic levels. This is helping the market to witness a progressive growth in the pandemic crisis. 

Conversely, the availability of alternative technology and the high costs associated with the LAA closure devices is likely to hamper the market growth in the near future. The report includes detailed analysis on drivers, restraints, challenges, major segments, growth opportunities and strategic growth by market players to better apprehend the effect of COVID-19 pandemic on the global market.

COVID-19 Impact on Left Atrial Appendage Closure Devices Market Report Highlights:

   • The CAGR of the left atrial appendage closure devices market as estimated before the outbreak of COVID-19 pandemic was 23.1% over the forecast period.
   • The CAGR of the global industry, as projected post the onset of COVID-19 crisis, is expected to grow at 24% during the forecast period.
   • The market size of the left atrial appendage closure devices industry in 2020, as estimated before the COVID-19 pandemic began was $572.9 million.
   • The real-time market size in 2020, bearing the after-effects of the COVID-19 pandemic is $585.2 million

Download a sample analysis report on the LAA closure devices market.

Current LAA Closure Market Transformation During COVID-19 Crisis

The LAA closure devices industry is likely to experience a surge in the growth rate during the coronavirus pandemic. The governments of various countries are taking initiatives to create awareness amongst people regarding the importance of left atrial appendage closure devices during the pandemic, which is the major factor expected to boost the market growth in 2020. Besides, a number of manufacturers are stressing their activities on product improvements to obtain a strong position and sustain in the global market in coronavirus emergency. 

For instance, in February 2020, Abbott received the U.S. Food and Drug Administration (FDA) approval for its newly innovated Amplatzer Amulet Left Atrial Appendage Occluder, which is designed for AF patients. This is expected to create lucrative opportunities in the market in the trying times.

Post-Pandemic LAA Closure Market Landscape

As per the report, the global LAA closure devices market is anticipated to witness a tremendous growth even after the COVID-19 pandemic. The continuous advancements in technology, government support for medical device approvals, rise in number of ambulatory clinical centers globally, and developments by prominent market players are the major factors expected to bolster the market growth.

The key players operating in the global industry include:
   • Boston Scientific Corp.
   • SentreHEART Inc.
   • AtriCure Inc.
   • Occlutech
   • Abbott
   • Lifetech Scientific
   • Aegis Medical Group.
   • Cardia Inc.
   • Johnson & Johnson Services Inc.
   • Biosense Webster Inc.

The report also summarizes other important aspects of the key players including Financial Performance, Product Portfolio, SWOT analysis, and Recent Strategic moves and developments. 

Read more about the thee most commonly used LAA closure devices across the globe are the Watchman, Lariat and the Amplatzer.  

Research Dive is a market research firm based in Pune, India. Scrutinizing relevant news releases, government publications, decades of trade data, and technical and white papers, Research Dive delivers the required services to its clients well within the required timeframe. 

Get Sample Report [75 pages]

For more information: www.researchdive.com

 

Related LAA Occlusion Device Content:

AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices

Conformal Medical Secures $85 Million in Funding for Left Atrial Appendage Occluder Trial

VIDEO: Overview of LAA Occlusion Using the Watchman FLX

FDA Clears Next-generation Watchman FLX Left Atrial Appendage Occluder

Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial

First-Of-Its-Kind, No-Implant LAA Occluder Noted for Innovation at 2019 ICI Meeting

Find more LAA occluder news and video

Related Content

Ablation and Biventricular Pacing Boosts Survival in Selected Atrial Fibrillation Patients in APAF-CRT Trial. #ESC #ESCcongress
News | Atrial Fibrillation | September 13, 2021
September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate contro
The Medtronic Linq II implantable cardiac monitor.

The Medtronic Linq II implantable cardiac monitor.

News | Atrial Fibrillation | September 08, 2021
September 8, 2021 — Continuous heart rhythm monitoring – with...
The Adagio Medical iCLAS cryoablation system is commercial in Europe and is also part of an ongoing FDA IDE trial in the U.S. #HRS21
News | Atrial Fibrillation | August 09, 2021
August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for...
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up